Physician profile
Thomas P Waring
NPI 1588812564
$13,440.73
in general payments reported to CMS, 2019-2025
20 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $147 · 2021: $99.92 · 2022: $447 · 2023: $6,812 · 2024: $3,592 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,556 · Travel and Lodging: $2,374 · Food and Beverage: $2,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,556.12 |
| Travel and Lodging | $2,374.12 |
| Food and Beverage | $2,264.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,502.84 | 2023-2025 | Da Vinci Surgical System |
| Penumbra, INC. | $2,667.45 | 2022-2025 | Indigo System, Penumbra System, Ruby Coil |
| Livanova USA, INC. | $406.98 | 2022-2023 | Lifesparc |
| Glaxosmithkline, LLC. | $347.59 | 2019-2025 | Nucala, Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $326.72 | 2019-2020 | |
| Olympus America INC. | $320.64 | 2022-2025 | Spiration Valve System, Spin Thoracic Navigation System, 120v, 60hz |
| Gilead Sciences, INC. | $263.84 | 2021-2024 | Veklury |
| Actelion Pharmaceuticals US, INC. | $140.78 | 2019-2024 | Uptravi |
| Insmed, INC. | $126.90 | 2020-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.05 | 2020-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $73.49 | 2025 | Tezspire |
| Veran Medical Technologies, INC. | $40.81 | 2019-2020 | |
| Mylan Specialty L.P. | $27.44 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $23.35 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $16.65 | 2025 | Fasenra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $16.44 | 2024 | Smartvest |
| Csl Behring | $14.64 | 2021 | |
| Siemens Medical Solutions USA, INC. | $14.39 | 2024 | Cios Spin |
| Resmed Corp | $14.14 | 2021 | |
| Pfizer INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Waring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.